Relationship between Tumor Infiltrating Lymphocytes and Neoadjuvant Chemoterapy Responsiveness: A Cross-Sectional Study on Breast Cancer Patients
Main Article Content
Abstract
Breast cancer is still a significant health problem in the world, with chemotherapy as an essential component in its management. Limited research on tumor- infiltrating lymphocytes (TIL) as a biomarker for the effectiveness of breast cancer treatment was conducted and is still contradictory. This study aims to investigate the relationship between TILs and the clinical response to neoadjuvant chemotherapy in breast cancer. The research used a cross-sectional study on eligible breast cancer patients in Wahidin Sudirohusodo Hospital in Makassar. TIL levels were grouped based on the histopathological examination results of breast tissue samples into three categories: low (0% to 10%), medium 15% to 50% and high (55% to 100%). Responsiveness was assessed based on changes in tumor size after neoadjuvant chemotherapy. The Chi-Square test is the primary analysis in this study. Results of 40 participants, the sample had a median age of 40 (27-73 years), mainly in the clinical stage III (40.0%), had moderate TIL concentration (47.5%), and was responsive to the neoadjuvant chemotherapy (87.5%). There was no significant association between TIL concentration and chemotherapy responsiveness (p > 0.05). However, in post-chemotherapy conditions, the median value of tumor size in the group with the high TIL category was significantly lower than in the low and medium TIL groups (p=0.034). There was no association between TIL levels and the clinical response to neoadjuvant chemotherapy in breast cancer patients. Further research is needed to confirm these findings.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et 10 al.(2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 71(3):209–49.
II. The International Agency for Cancer Research. GLOBOCAN 2020: New Global Cancer Data | UICC [Internet]. 2020 [cited 2024 Jan 18]. Available from: https://www.uicc.org/news/globocan-2020-new-global-cancer-data
III. Gong C, Yao H, Liu Q, Chen J, Shi J, Su F, et al. (2010). Markers of Tumor- Initiating Cells Predict Chemoresistance in Breast Cancer. PLOS ONE. 20;5(12):e15630.
IV. Hicklin DJ, Ellis LM. (2005). Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 10;23(5):1011–27.
V. Lee A, Lim W, Moon BI, Paik NS, Koh SH, Song JY. (2011). Chemotherapy Response Assay Test and Prognosis for Breast Cancer Patients Who Have Undergone Anthracycline- and Taxane-Based Chemotherapy. J Breast Cancer. 14(4):283–8.
VI. Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, et al. (2020). Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 18(4):452–78.
VII. Liu Y, Du F, Chen W, Yao M, Lv K, Fu P. (2013). Knockdown of dual specificity phosphatase 4 enhances the chemosensitivity of MCF-7 and MCF-7/ADR breast cancer cells to doxorubicin. Exp Cell Res. 319(20):3140–9.
VIII. Gao ZH, Li CX, Liu M, Jiang JY. (2020). Predictive and prognostic role of tumour- infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis. BMC Cancer. 20(1):1150.
IX. Zgura A, Galesa L, Bratila E, Anghel R. (2018). Relationship between Tumor Infiltrating Lymphocytes and Progression in Breast Cancer. Maedica (Bucur). 13(4):317–20.
X. Giovanno A, Saleh MI, Qodir N, Umar M. (2020). Neoadjuvan Chemotherapy Response to Local Advanced Breast Cancer Patients at Dr Mohammad Hoesin Hospital Palembang. Sriwijaya Journal of Medicine. 3(3):51–8.
XI. Iseki Y, Shibutani M, Maeda K, Nagahara H, Fukuoka T, Matsutani S, et al. (2018). A new method for evaluating tumor-infiltrating lymphocytes (TILs) in colorectal cancer using hematoxylin and eosin (H-E)-stained tumor sections. PLoS One. 13(4):e0192744.
XII. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45(2):228–47.
XIII. Sampepajung D. (2010). Breast Cancer in Indonesia, Problems and Overcome. Manuscript of Speech at the Inauguration Ceremony as Professor of Surgical Oncology, Faculty of Medicine, Hasanuddin University.
XIV. PERABOI. (2023). Guidelines on the management of breast cancer. Jakarta.
XV. Dyanti GAR, Suariyani NLP. (2016). Factors for Delays in Breast Cancer Patients in Carrying Out Initial Examinations With Health Services. Kemas. 25;11(2):276.
XVI. Santhi IGAK, Christian INWS, Widiana IGR. (2019). The relationship between TIL (Tumor Infiltrating Lymphocyte) and MAI (Mitotic Activity Index) with the incidence of axillary lymph node (KGB) metastases in operable breast cancer at
XVII. Sanglah General Hospital, Denpasar. Intisari Sains Medis 10(2): 465-70.
XVIII. Diana D, Kusmardi. (2020). Tumor infiltrating lymphocytes and their role in breast carcinoma. 29(1):30–40.
XIX. Dutta S, Ganguly A, Chatterjee K, Spada S, Mukherjee S. (2023). Targets of
XX. Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors. Biology. 12(2):218.
XXI. Wang K, Xu J, Zhang T, Xue D. (2016). Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta- analysis. Oncotarget. 7(28):44288–98.